Nutraveris

Archives

Thursday, December 29, 2016
Category : News, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

This randomized, double-blind, and placebo-controlled trial examined the effects of a maslinic acid supplement (a bioactive pentacyclic triterpenoid), olive fruit extract (Olea europaea L.), on 20 middle-aged and elderly volunteers with mild knee joint pain.

Each subject (58 ± 7 years) received either olive fruit extract, containing 50 mg maslinic acid (n = 12), or placebo (n = 8) daily for 12 weeks and evaluated for pain and physical functions.

Although both groups exhibited improved pain visual analogue scale score and quality of life after supplementation, symptoms were better in the maslinic acid group than in the placebo group. After 12 weeks, maslinic acid group exhibited significant decrease in body weight and body mass index suggesting that maslinic acid affected the weight of volunteers with mild knee joint pain.

Therefore, olive products containing maslinic acid may be useful as a new preventive and therapeutic food ingredient for arthritic diseases.

VAS joint pain in maslinic acid group compared to the placebo group

Fukumitsu S, Villareal MO, Aida K, Hino A, Hori N, Isoda H, Naito Y. Maslinic acid in olive fruit alleviates mild knee joint pain and improves quality of life by promoting weight loss in the elderly. J Clin Biochem Nutr. 2016 Nov;59(3):220-225.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

More information on www.nutraveris.com

Contactez nos experts scientifiques et réglementaires à:  NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, December 27, 2016
Category : News, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

This clinical trial aimed to evaluate long-term chamomile (Matricaria chamomilla L.) use for prevention of generalized anxiety disorder symptom relapse.

A total of 179 patients with a primary diagnosis of moderate-to-severe generalized anxiety disorder were enrolled for this study.

During Phase 1, eligible participants received 12 weeks of open-label therapy with chamomile pharmaceutical grade extract 1500 mg.

During Phase 2, treatment responders were given either 26 weeks of continuation chamomile therapy or placebo in a double-blinded, placebo-substitution design.

Mean time to relapse was 11.4 ± 8.4 weeks for chamomile and 6.3 ± 3.9 weeks for placebo. During follow-up, chamomile participants maintained significantly lower generalized anxiety disorder symptoms than placebo (p = 0.0032), with significant reductions in body weight (p = 0.046) and mean arterial blood pressure (p = 0.0063).

chamomille-and-anxiety-disorder

Mean weight change in kg

Long-term chamomile was safe and significantly reduced moderate-to-severe generalized anxiety disorder symptoms, but did not significantly reduce rate of relapse.

 

Mao JJ, Xie SX, Keefe JR, Soeller I, Li QS, Amsterdam JD. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial. Phytomedicine. 2016 Dec 15;23(14):1735-1742.

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

 

Thursday, December 15, 2016
Category : News, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

pomegranate

Pomegranate has been claimed to reduce the risk of cardiovascular diseases. However, the effects of pomegranate remain unclear. This meta-analysis aimed therefore to clarify the effects of pomegranate juice on blood pressure.

8 randomized and controlled studies have been included in the analysis, for a total of 574 individuals. They received pomegranate juice for 2 weeks to 18 months. Two studies were conducted in healthy volunteers, whereas the 6 other studies were conducted in patients with cardiovascular risk factors or cardiovascular diseases.

Results showed reductions in systolic (-4.96 mmHg, 95% CI: -7.67 to -2.25, p < 0.001) and diastolic blood pressure (-2.01 mmHg, 95% CI: -3.71 to -0.31, p = 0.021) after pomegranate juice. The effects of pomegranate juice on systolic blood pressure were independent of supplementation length (<12 weeks vs. > 12 weeks) and of dose consumed (<240 cc vs. >240 cc).

The authors concluded that pomegranate juice effectively reduce blood pressure and propose to include this juice in heart-healthy diets.

 

Sahebkar A, Ferri C, Giorgini P, Bo S, Nachtigal P, Grassi D. Effects of Pomegranate Juice on Blood Pressure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Pharmacol Res. 2016 Nov 22. pii: S1043-6618(16)30784-8.

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

 

Tuesday, December 13, 2016
Category : News, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

In the present study, the effective dose of kale (Brassica oleracea var. acephala)-containing food was investigated in a randomized, double-blind, placebo-controlled, crossover trial.

The trial was conducted on 42 Japanese subjects aged 21-64 years with fasting plasma glucose levels of ≤125 mg/dl and 30-min postprandial plasma glucose levels of 140-187 mg/dl. The subjects consumed placebo or kale-containing food [7 or 14 g; low-dose (active-L) or high-dose (active-H) kale, respectively] together with a high-carbohydrate meal. At 30-120 min after the test meal intake, the plasma levels of glucose and insulin were determined.

The postprandial plasma glucose levels in subjects with intake of active-L or active-H were significantly lower than those in subjects with intake of placebo, with the maximum plasma concentration (Cmax; 163±24 mg/dl for active-L and 162±23 mg/dl for active-H compared with 176±26 mg/dl for placebo [values presented as means ± standard deviation (SD); P<0.01]. The area under the plasma glucose concentration-time curve for 0-2 h (AUC0-2 h) values (means ± SD) were significantly lower for active-L (268±43 mg/h/dl) and active-H (266±42 mg/h/dl) than for the placebo (284±43 mg/h/dl; P<0.05).

No significant differences were identified in the postprandial plasma insulin levels between the three conditions.

kale-and-plasma-glucose

Results suggest kale suppresses postprandial increases in plasma glucose levels at a single dose of 7 g, and that a dose as high as 14 g is safe.

Kondo S, Suzuki A, Kurokawa M, Hasumi K. Intake of kale suppresses postprandial increases in plasma glucose: A randomized, double-blind, placebo-controlled, crossover study. Biomed Rep. 2016 Nov;5(5):553-558..

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

More information on www.nutraveris.com

 

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Friday, December 9, 2016
Category : News | Author : experts | Comment : No Comments
Tags:

HIE Nutraveris'Booth

 

Held once every two years, after Amsterdam in 2014, this great event took place this year in Frankfurt from November 29 to December 1st, and has attracted a large number of visitors.

The HIE is one of the main Professional European event dedicated to functional foods, food supplements and natural ingredients.

HIE

At the 20th edition of Health Ingredients Europe, Nutraveris’ booth has been very successful. A lot of Nutrition and Health professionals had the opportunity to learn about the benefits offered by our services:

  • Regulatory compliance : Composition & Communication.
  • Product registration : in the 28 European member states.
  • Scientific substantiation : Health claim & Novel food.
  • Formulation : Innovative, Substantiated Product development.
  • Regulatory, Scientific, Marketing Intelligence : NOL Data Solution, a complete collaborative tool to formulate, analyze and update your products in the 28 Member States of the European Union.

HIE Nutraveris'booth

Nutraveris'booth at HIE